Trials / Completed
CompletedNCT00420056
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
A Pilot Study Of Pd 0332991 In Patients With Previously Treated Mantle Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
This is a pilot study evaluating tumor activity using Positron Emission Tomography, which is also known as a "PET scan". This study will assess the safety of using PD-0332991 in patients with mantle cell lymphoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PD-0332991 | 125 mg, oral, Days 1-21 of a 28-day cycle |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2010-03-01
- Completion
- 2012-03-01
- First posted
- 2007-01-09
- Last updated
- 2015-10-28
- Results posted
- 2015-06-09
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00420056. Inclusion in this directory is not an endorsement.